Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biotech company, announced that formulation feasibility studies support the potential for intranasal delivery of its proprietary compound MEAI (5-Methoxy-2-aminoindane), which is being developed as a treatment for alcohol use disorder (AUD).

According to the company, the studies demonstrated that MEAI can be incorporated into a formulation system, producing a stable and fully soluble solution. The results are intended to support continued development of intranasal administration as an additional route of delivery for the compound.

Clearmind said the intranasal program is at an early stage, with initial work focused on assessing the compound's compatibility with the formulation system. The company stated that the findings provide a basis for subsequent formulation optimization activities.

MEAI is Clearmind's lead therapeutic candidate and has been evaluated in preclinical and clinical studies targeting compulsive alcohol consumption and related behaviors. The company said the intranasal delivery program is intended to evaluate whether this route of administration can complement existing delivery approaches.

"This development program represents our ongoing efforts to maximize the therapeutic potential of MEAI," said Dr. Adi Zuloff-Shani, CEO of Clearmind. "We believe that the successful formulation feasibility results support the potential of intranasal delivery of MEAI and provide a strong basis for further formulation optimization."

Clearmind is listed on the Nasdaq exchange under the ticker symbol CMND. The company holds a portfolio of 19 patent families, including 32 granted patents.